Bionano Genomics, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bionano Genomics, Inc. on August 24, 2020. The filing primarily addresses the appointment of a new Chief Financial Officer (CFO) effective September 1, 2020.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change is the appointment of Christopher Stewart as Chief Financial Officer, replacing R. Erik Holmlin, Ph.D. (CEO) and Mark Adamchak (Controller), who had been serving in interim financial roles. Mr. Stewart brings over 20 years of experience, including roles at Tesla, Inc. (Maxwell Ultracapacitors), Maxwell Technologies, Entropic Communications, and V-ENABLE Inc.
Employment Agreement and Compensation
- Base Salary: $54,080 for the remainder of calendar year 2020; $305,000 annually commencing January 1, 2021.
- Bonus: Discretionary cash bonus up to $30,500 for 2020; up to 30% of base salary annually thereafter.
- Equity Awards:
- Initial Option: 350,000 shares vesting over four years (25% after one year, monthly thereafter).
- Additional Option: 225,000 shares vesting in full on December 31, 2020.
- Severance: Upon termination without cause or resignation for good reason, Mr. Stewart is entitled to six months of salary continuation and COBRA reimbursement. Unvested Additional Options vest immediately if termination occurs on or before December 31, 2020. Unvested Initial Options vest immediately if termination occurs within 24 months of a Change in Control.
Risks and Contingencies
Severance benefits are contingent upon Mr. Stewart's compliance with continuing obligations and the execution of a general release. The filing notes that the description of the Employment Agreement is qualified by reference to the full agreement, which will be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2020.
Investor Verification Checklist
- Verify the grant date and exercise price of the stock options once the Board approves the awards.
- Review the full Employment Agreement in the upcoming Form 10-Q for detailed terms regarding "Cause" and "Good Reason."
- Monitor the vesting schedule of the 225,000 Additional Option shares, which vest entirely by year-end 2020.
- Confirm the transition of financial reporting responsibilities from interim officers to Mr. Stewart.